Healios KK (HLOSF) Stock Price, Trades & News

Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	4.2
Equity-to-Asset	0.32
Debt-to-Equity	0.34
Debt-to-EBITDA	-1.31
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.1	Distress Grey Safe
Beneish M-Score	19.85	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-10
	3-Year EBITDA Growth Rate	38.3
	3-Year EPS without NRI Growth Rate	33.6
	3-Year FCF Growth Rate	24.4
	3-Year Book Growth Rate	-15.2
	Future 3-5Y Total Revenue Growth Rate Estimate	300.23

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	0.03
	9-Day RSI	0.9
	14-Day RSI	4.71
	3-1 Month Momentum %	-33.33
	6-1 Month Momentum %	-6.74
	12-1 Month Momentum %	-43.22

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.05
	Quick Ratio	2.05
	Cash Ratio	1.88
	Days Sales Outstanding	1058.5
	Days Payable	526.06

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-22.3
	Shareholder Yield %	-23.7

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	-155.41
	Operating Margin %	-5035.14
	Net Margin %	-4233.78
	EBITDA Margin %	-2679.73
	FCF Margin %	-5171.63
	OCF Margin %	-4916.53
	ROE %	-84.3
	ROA %	-17.33
	ROIC %	-24.33
	3-Year ROIIC %	49.91
	ROC (Joel Greenblatt) %	-232.08
	ROCE %	-17.52
	Moat Score	3
	Tariff Resilience Score	7

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	352.94
	PB Ratio	4.4
	Price-to-Tangible-Book	10.59
	EV-to-EBIT	-11.04
	EV-to-EBITDA	-12.59
	EV-to-Revenue	337.3
	EV-to-FCF	-6.46
	Price-to-GF-Value	4.29
	Earnings Yield (Greenblatt) %	-9.06
	FCF Yield %	-11.64

GF Value™: $0.42

HLOSF

Warning Signs

Warning! GuruFocus detected 5 Severe warning signs with HLOSF. Try a 7-Day Free Trial to check it out.

Healios KK Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Healios KK Stock Events

Financials Calendars

	Event	Date	Price ($)
No Event Data

Guru Commentaries on OTCPK:HLOSF

No articles.

Press Release

	Subject	Date
	Healios Successfully Establishes Proprietary Universal Donor Cell Research Line	2020-06-05
	COVID-19 ARDS Patients Added to Healios ONE-BRIDGE Study	2020-04-14
	Regarding HLCM051 for Acute Respiratory Distress Syndrome (ARDS) Caused by COVID -19	2020-03-26
	Announcement of iPSC Derived Gene-modified NK Cell Development Targeting Solid Tumors	2020-01-10
	Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, CA	2020-01-09

10/Page

Articles on Healios KK

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.